Thursday, November 13, 2008

An Apparently-Typical Vytorin Salesperson's Lament -- in Plain Language -- Over at CafePharma. . . .


Below appears an un-edited CafePharma post -- true, it is anonymous, but it does ring in as accurate -- and clear:

Yesterday, 03:20 PM
BY: Anonymous

Re: Zetia/Vytorin

. . . .Had a high-volume doc tell me today he is no longer prescribing Zetia or Vytorin and not to discuss these two drugs with him anymore. What the hell does SP expect me to do about this? He told me that I am a good rep and he respects me a lot, but that he no longer will prescribe or discuss these two drugs. . . .

Do go read the responses to this anonymous lament. They are enlightening, and honest.

That is all.

2 comments:

Anonymous said...

Are you familiar with the government's site for clinical trials?

Here's the first page associated with S/P...note that their Hep C compound is starting a Ph3 study.

http://www.clinicaltrials.gov/ct2/results?spons=%22Schering-Plough%22&spons_ex=Y&pg=1

Seems it remains well behind Vertex.

Condor said...

I am. And I think your surmise is correct -- Vertex is, in fact, well-in-the-lead -- and would appear to have the more robust efficacy profile (working in non-responders!) for Hep C.

I'll likely write another update to "The Teleprevir Chronicles" soon!

Thanks!